ABT:NYE-Abbott Laboratories

EQUITY | Medical Devices | New York Stock Exchange

Last Closing Price

USD 69.95

Change

0.00 (0.00)%

Market Cap

USD 122.86B

Volume

7.95M

Average Target Price

USD 78.72 (12.54%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-12-09 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
MDT Medtronic plc.

N/A

USD 126.57B
SYK Stryker Corporation

N/A

USD 63.18B
BSX Boston Scientific Corporation

N/A

USD 49.10B
EW Edwards Lifesciences Corporati..

N/A

USD 32.86B
ZBH Zimmer Biomet Holdings Inc.

N/A

USD 22.42B
SNN Smith & Nephew SNATS Inc.

N/A

USD 16.59B
PEN Penumbra Inc.

N/A

USD 4.54B
GMED Globus Medical Inc. Class A

N/A

USD 4.51B
ITGR Integer Holdings Corporation

N/A

USD 2.71B
NVRO Nevro Corp.

N/A

USD 1.25B

ETFs Containing ABT

FTXH First Trust Nasdaq Pharma.. 10.48 % 0.60 %

N/A

USD 4.19M
IHI iShares U.S. Medical Devi.. 9.88 % 0.43 %

N/A

USD 2.92B
PJP Invesco Dynamic Pharmaceu.. 5.79 % 0.57 %

N/A

USD 0.51B
LIFE.B:CA Evolve Global Healthcare .. 5.09 % 0.67 %

N/A

CAD 1.04M
LIFE:CA Evolve Global Healthcare .. 5.09 % 0.66 %

N/A

CAD 1.44M
ACT AdvisorShares Vice ETF 5.09 % 0.00 %

N/A

USD 0.01B
PILL Direxion Daily Pharmaceut.. 4.33 % 0.00 %

N/A

USD 4.01M
PWB Invesco Dynamic Large Cap.. 3.89 % 0.57 %

N/A

USD 0.64B
XLV SPDR Select Sector Fund -.. 3.51 % 0.14 %

N/A

USD 19.01B
IYH iShares U.S. Healthcare 3.33 % 0.43 %

N/A

USD 2.45B
HECO Strategy Shs EcoLogical 3.16 % 0.95 %

N/A

USD 0.01B
FHLC Fidelity MSCI Health Care.. 3.02 % 0.08 %

N/A

USD 1.61B
VHT Vanguard Health Care 3.01 % 0.10 %

N/A

USD 8.82B
VIG Vanguard Div Appreciation 2.65 % 0.08 %

N/A

USD 29.70B
IXJ iShares Global Healthcare 2.50 % 0.47 %

N/A

USD 1.74B
JHMH John Hancock Multifactor .. 2.24 % 0.50 %

N/A

USD 0.06B
CCOR Cambria Core Equity 2.17 % 1.21 %

N/A

USD 0.08B
JKD iShares Morningstar Large.. 2.01 % 0.20 %

N/A

USD 0.88B
FTHI First Trust High Income E.. 1.99 % 0.85 %

N/A

USD 0.06B
FTLB First Trust Low Beta Inco.. 1.92 % 0.85 %

N/A

USD 0.01B
RYH Invesco S&P 500 Equal Wei.. 1.75 % 0.40 %

N/A

USD 0.70B
XHE SPDR S&P Health Care Equi.. 1.74 % 0.35 %

N/A

USD 0.63B
ZUH:CA BMO Equal Weight US Healt.. 1.72 % 0.39 %

N/A

CAD 0.39B
FDMO Fidelity Momentum Factor 1.67 % 0.29 %

N/A

USD 0.10B
JMIN JPMorgan U.S. Minimum Vol.. 0.64 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.57% 62% D- 95% A
Dividend Return 1.96% 83% B 41% F
Total Return 24.53% 62% D- 95% A
Trailing 12 Months  
Capital Gain 28.02% 62% D- 96% A
Dividend Return 2.05% 83% B 37% F
Total Return 30.07% 62% D- 95% A
Trailing 5 Years  
Capital Gain 88.04% 36% F 91% A-
Dividend Return 13.60% 86% B 47% F
Total Return 101.64% 36% F 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 13.52% 38% F 84% B
Dividend Return 15.86% 38% F 85% B
Total Return 2.34% 100% A+ 46% F
Risk Return Profile  
Volatility (Standard Deviation) 19.30% 69% D+ 36% F
Risk Adjusted Return 82.17% 46% F 73% C
Market Capitalization 56.45B 93% A 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 139.90 14% F 3% F
Price/Book Ratio 4.02 64% D 17% F
Price / Cash Flow Ratio 5.00 57% F 22% F
Price/Free Cash Flow Ratio 24.98 54% F 21% F
Management Effectiveness  
Return on Equity 2.87% 43% F 31% F
Return on Invested Capital 6.25% 50% F 38% F
Return on Assets 1.23% 36% F 37% F
Debt to Equity Ratio 76.25% 58% F 49% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.